Diagnosis of CeD begins with serologic testing, most commonly anti-tissue transglutaminase Immunoglobulin A (anti-TTG IgA), which has high sensitivity and specificity [17]. This evidence concerns the gene TGM2 and cranioectodermal dysplasia.